A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)

Status: Recruiting

Eligibility Criteria

Age: 18 years and over

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

• Signed informed consent

• Have diagnosis of RMS, including RRMS and aSPMS, and satisfy the approved indication for cladribine tablets as per United States Prescribing Information (USPI)

• Have time since diagnosis of RMS of at least 12 months

• In the opinion of the investigator, experienced suboptimal response (lack of effectiveness, intolerability, poor adherence) to oral or infusion DMD treatment other than cladribine tablets

• Had received their last previous oral DMD for at least 1 month or at least 1 dose of their last previous infusion DMD

• Have decided to initiate treatment with cladribine tablets during routine clinical care

• Meet criteria as per the approved USPI

• Have access to a valid e-mail address

Exclusion Criteria:

• Have been previously treated with cladribine in any dosing form (intravenous, subcutaneous, or oral)

• Transitioning from previous oral DMD solely for administrative reasons such as relocation

• Have comorbid conditions that preclude participation

• Have any clinical condition or medical history noted as contraindication on USPI

• Are currently participating in an interventional clinical trial

• Pregnant or breastfeeding women, women who plan to become pregnant or men whose partner plans to become pregnant during study the cladribine treatment period

Conditions & Interventions

Interventions:
Drug: Cladribine Tablets
Conditions:
Multiple Sclerosis
Keywords:
Multiple Sclerosis, Cladribine Tablets, Observational, Mavenclad

More Information

Contact(s): US Medical Information - eMediUSA@emdserono.com
Principal Investigator:
Phase:
IRB
Number:
System ID: NCT03933202
